Magle Group initiates collaboration with leading German university hospital to explore synergies between EmboCept® S DSM 50 µm and immunotherapies

21/11/2023

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-06-28 11:05 announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy.

As a first step of the collaboration, the parties are planning a study to explore the immune-modulating effect of EmboCept® S DSM 50 µm when administered in a preclinical research model of hepatocellular carcinoma. “The establishment of this prestigious collaboration with a leading German research group at Charité Berlin is part of Magle’s continued efforts to improve patient impact by developing and extending the medical use of our existing DSM-based product line,“ says Justin Pierce, CEO of Magle Group. EmboCept® S DSM 50 µm is a CE-marked medical device for vascular occlusion